| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11015065 | International Journal of Cardiology | 2018 | 26 Pages |
Abstract
In AAHF patients, who remain symptomatic despite OMM, LEVO is well tolerated and associated with lower overall length of hospital stay during six months. This multicentre clinical experience underscores the need for a randomized controlled trial of LEVO impact on outcomes in AAHF patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Fabrizio Oliva, Enrico Perna, Marco Marini, Daniele Nassiacos, Antonio Cirò, Gabriella Malfatto, Fabrizio Morandi, Ivan Caico, Gianpiero Perna, Sabina Meloni, Antonella Vincenzi, Alessandra Villani, Andrea Lorenzo Vecchi, Chiara Minoia,